Endoscopy 2015; 47(06): 538-540
DOI: 10.1055/s-0034-1391395
Case series
© Georg Thieme Verlag KG Stuttgart · New York

Gastric antral vascular ectasia: a prospective study of treatment with endoscopic band ligation

Sergio Zepeda-Gómez
1   Division of Gastroenterology, University of Alberta Hospital, Edmonton, Alberta, Canada
,
Richard Sultanian
1   Division of Gastroenterology, University of Alberta Hospital, Edmonton, Alberta, Canada
,
Christopher Teshima
1   Division of Gastroenterology, University of Alberta Hospital, Edmonton, Alberta, Canada
,
Gurpal Sandha
1   Division of Gastroenterology, University of Alberta Hospital, Edmonton, Alberta, Canada
,
Sander Van Zanten
1   Division of Gastroenterology, University of Alberta Hospital, Edmonton, Alberta, Canada
,
Aldo J. Montano-Loza
2   Division of Hepatology, University of Alberta Hospital, Edmonton, Alberta, Canada
› Author Affiliations
Further Information

Publication History

submitted 12 November 2014

accepted after revision 07 December 2014

Publication Date:
04 February 2015 (online)

Preview

Gastric antral vascular ectasia (GAVE) is characterized by red, angiomatous lesions in the antrum organized either in stripes or in a diffuse pattern that can be associated with upper gastrointestinal bleeding. Endoscopic band ligation (EBL) has been reported as an effective alternative therapy for patients with GAVE. Consecutive patients with a diagnosis of GAVE were prospectively followed while undergoing EBL every 2 months. Hemoglobin, ferritin, and iron levels were frequently recorded, and clinical follow-up was performed. A total of 21 patients with GAVE were enrolled, and 17 of these patients (81 %) had associated co-morbidities, most frequently cirrhosis and chronic renal failure. A clinical response was achieved in 19 patients (91 %). A significant improvement in the mean hemoglobin level was noted after EBL (P < 0.001), and a significant decrease in blood transfusion requirements per month (P = 0.001). No major complications were observed during the study period. The mean follow-up was 10 months. EBL is an effective and safe treatment for GAVE. Randomized, controlled trials comparing EBL with other endoscopic therapies are warranted.